AL-605

AL-605 is a research-stage compound developed by Alcon (a subsidiary of Novartis at the time of development) primarily investigated for ophthalmic applications. While specific details on its mechanism of action are limited in broad clinical literature, it belongs to a series of compounds explored for the treatment of ocular hypertension and glaucoma. The 'AL' prefix is characteristic of Alcon's internal development pipeline, which has historically focused on small molecule therapeutics for anterior and posterior segment eye diseases. Development of AL-605 appears to have been discontinued or superseded by other assets in the Alcon/Novartis portfolio, as it has not progressed into late-stage clinical trials or commercialization.